Pediatric research explored environmental interventions for bronchiolitis, heart function in children born preterm, and a ...

Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center, speaks about the clinical and operational priorities that ...

Jonathan Strober, MD, explains the initial presentation of myasthenia gravis in a pediatric patient population and why initial diagnosis for these patients can be challenging.

Panelists discuss how proactive patient education, lipid-lowering interventions, and monitoring tools can help patients stay ...

Panelists discuss how step-therapy for immunoglobulin A (IgA) nephropathy is evolving toward a more personalized approach, ...

Recent research reveals COVID-19 significantly increases long-term kidney dysfunction risk compared with influenza, ...

Congress is unlikely to codify the recent executive order to lower drug pricing as other US officials negotiate new prices, John Barkett, MBA, of Berkeley Research Group, explains.

The repeal of the federal rule could leave those with mental health and substance use disorders at risk of losing coverage for their treatment.

Panelists discuss how lorlatinib’s unique adverse event (AE) profile, including cognitive effects, hypercholesterolemia, and peripheral neuropathy, impacts treatment selection and patient management.

Panelists discuss how patient-reported outcomes including symptom burden, treatment-related adverse effects, preserved functionality, and impact on quality of life should be prioritized alongside ...

Gastropsychiatrist Eva Svigethy, MD, PhD, and Benjamin Cohen, MD, Cleveland Clinic, discuss quality of life improvement in ...

SCAN Group takes ownership of an integrated care delivery organization, to expand its impact on the lives of vulnerable ...